Long-Term Study of COVID-19 Infection and Long COVID
NCT07781501 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2026-08-24
Summary
This study will examine how common Long COVID is and how symptoms may persist over time in people who have previously had COVID-19. Researchers will collect information about participants' health and symptoms through questionnaires and may collect saliva and other non-invasive oral samples. The study will also examine biological factors in these samples that may be associated with persistent symptoms. The goal is to better understand why some people develop Long COVID and identify factors that may help predict who is more likely to experience persistent symptoms.
Conditions
- SARS CoV-2 Post-Acute Sequelae
Interventions
- OTHER
-
This study is observational. Only patients who have previously tested positive for SARS-CoV-2 infection or are experiencing ongoing symptoms.
Other:
Sponsors & Collaborators
-
National Institute of Dental and Craniofacial Research (NIDCR)
collaborator NIH -
University of North Carolina, Chapel Hill
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-09-04
- Primary Completion
- 2028-12-31
- Completion
- 2029-12-31
Countries
- United States
Study Locations
More Related Trials
-
Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling
NCT01217359 ·Status: COMPLETED ·Phase: PHASE1
-
Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
NCT01492426 ·Status: COMPLETED ·Phase: PHASE3
-
Natural History of Hepatitis C in Patients With Normal Liver Tests
NCT00187473 ·Status: COMPLETED
-
Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment
NCT02865369 ·Status: UNKNOWN
-
Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)
NCT00725842 ·Status: TERMINATED
-
Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients Previously Treated With Daclatasvir-Based Regimens
NCT03366610 ·Status: COMPLETED
-
Factors Associated to Success of Hepatitis C Therapy
NCT00514111 ·Status: COMPLETED
-
A 5-year Observational Follow-up Study to Describe Treatment Patterns in Real World of HCV Patients in China.
NCT01594554 ·Status: UNKNOWN
-
Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection
NCT01257204 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Describe the Actual Situation of Hepatitis C Treatment in Brazil
NCT02773394 ·Status: COMPLETED
-
Interferon α 2b Pharmacovigilance Study
NCT01841775 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)
NCT00874770 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
NCT01616524 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Drug Therapy for Patients With Hepatitis C
NCT00001729 ·Status: COMPLETED ·Phase: PHASE3
-
Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.
NCT01195181 ·Status: COMPLETED ·Phase: PHASE4
-
Reinfection and Long Term Outcomes in Intravenous Drug Users (IVDUs) After Hepatitis C Treatment
NCT01329952 ·Status: UNKNOWN
-
Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) Associated With Hepatitis C Virus (HCV)
NCT01545544 ·Status: UNKNOWN
-
4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients
NCT00905632 ·Status: COMPLETED ·Phase: PHASE1
-
PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)
NCT01056172 ·Status: UNKNOWN ·Phase: PHASE4
-
Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load
NCT00977054 ·Status: TERMINATED ·Phase: PHASE4
-
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
NCT00323804 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)
NCT01280656 ·Status: COMPLETED
-
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)
NCT01017575 ·Status: COMPLETED ·Phase: PHASE2
-
Timing and Duration of Acute Hepatitis C Treatment
NCT00241618 ·Status: COMPLETED ·Phase: PHASE4
-
Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis
NCT01769040 ·Status: COMPLETED ·Phase: PHASE4